AG881
AG881-C-001
Phase 1 small_molecule completed
Quick answer
AG881 for Acute Myeloid Leukemia (AML) is a Phase 1 program (small_molecule) at AGIOS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AGIOS PHARMACEUTICALS, INC.
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed